Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the adrisk trial

HIGHLIGHTS

• who: Susanne Wiegand et al. from the Japan Boston, United States Japan have published the research work: Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial, in the Journal: (JOURNAL)
• what: The aim of ADRISK is to show that addition of pembrolizumab to aRCT with cisplatin improves EFS compared with aRCT alone in locally advanced intermediate and high-risk HNSCC after surgery. The Javelin 100 phase III trial randomizing patients with locoregionally advanced HNSCC to cisplatin . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.